Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 456Magnetic Resonance Spectroscopy 347pembrolizumab 287Biopsy 245Carboplatin 228Cisplatin 194Cyclophosphamide 178Paclitaxel 160Nivolumab 153Gemcitabine 147Bevacizumab 126Radiotherapy 124Dexamethasone 110Pemetrexed 101fludarabine 96Fluorouracil 95atezolizumab 93Radiation 92Docetaxel 90venetoclax 89Doxorubicin 88durvalumab 85Oxaliplatin 85Rituximab 84Leucovorin 81Capecitabine 76Prednisone 73Lenalidomide 70X-Rays 69Etoposide 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paroxetine × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡